학술논문
Previous immune checkpoint inhibitor therapy is associated with decreased COVID-19-related hospitalizations and complications in patients with cancer: Results of a propensity-matched analysis of the OnCovid registry
Document Type
article
Author
Anahita Mostaghim; Samuel Minkove; Juan Aguilar-Company; Isabel Ruiz-Camps; Simeon Eremiev-Eremiev; Gino M. Dettorre; Laura Fox; Carlo Tondini; Joan Brunet; MCarmen Carmona-García; Matteo Lambertini; Mark Bower; Thomas Newsom-Davis; Rachel Sharkey; Alessia Dalla Pria; Maura Rossi; Andrea Plaja; Ramon Salazar; Anna Sureda; Aleix Prat; Vasiliki Michalarea; Mieke Van Hemelrijck; Ailsa Sita-Lumsden; Alexia Bertuzzi; Lorenza Rimassa; Sabrina Rossi; Gianpiero Rizzo; Paolo Pedrazzoli; Alvin JX Lee; Cian Murphy; Katherine Belessiotis; Nikolaos Diamantis; Uma Mukherjee; Fanny Pommeret; Annabelle Stoclin; Clara Martinez-Vila; Riccardo Bruna; Gianluca Gaidano; Francesca D'Avanzo; Alessandra Gennari; Janhavi Athale; Peter Eichacker; David J. Pinato; Parizad Torabi-Parizi; Alessio Cortellini
Source
International Journal of Infectious Diseases, Vol 139, Iss , Pp 13-20 (2024)
Subject
Language
English
ISSN
1201-9712
Abstract
Objectives: To date, studies have not provided definitive answers regarding whether previous immune checkpoint inhibitor (ICI) treatment alters outcomes for cancer patients with COVID-19. Methods: The OnCovid registry (NCT04393974) was searched from February 27, 2020, to January 31, 2022, for patients who received systemic anti-cancer therapy in the 4 weeks before laboratory-confirmed COVID-19 diagnosis. Propensity-score matching using country, vaccination status, primary tumor type, sex, age, comorbidity burden, tumor stage, and remission status investigated differences in predefined clinical outcomes comparing those who had or had not received ICIs. Results: Of 3523 patients screened, 137 ICI-only and 1378 non-ICI met inclusion criteria. Before matching, ICI patients were older, male, enrolled at centers in Italy, and had histories of smoking, thoracic cancers, advanced cancer stages, and active malignancies (P ≤0.02). After matching, there were 120 ICI and 322 non-ICI patients. ICI patients had no differences (odds ratio: 95% CI) in presenting COVID-19 symptoms (0.69: 0.37-1.28), receipt of COVID-specific therapy (0.88: 0.54-1.41), 14-day (0.95: 0.56-1.61), or 28-day (0.79: 0.48-1.29) mortalities. However, ICI patients required less COVID-19-related hospitalization (0.37: 0.21-0.67) and oxygen therapy (0.51: 0.31-0.83) and developed fewer complications (0.57: 0.36-0.92). Conclusion: In this propensity-score matched analysis, previous ICI therapy did not worsen and potentially improved COVID-19 outcomes in patients with cancer.